🔴 CMPS is trading 5.3% down today on Phase 3 depression trial durability data

CMPS is trading 5.3% down at $12.16 as investors react to 26-week durability data from its Phase 3 COMP006 trial for treatment-resistant depression.

• The company reported results from Part B of its Phase 3 psilocybin program on July 7, 2026, providing a key update on the long-term efficacy of the treatment.
• Shares are pulling back following a sharp multi-day rally and heightened market expectations leading up to the release of the durability data.